Hard-to-heal wounds represent a major Issue; medically, economically and pshycologically.
In many cases especially diabetic patients, the end solution is to amputate the wounded limb.
Roughly 50% of Diabetic Foot Ulcers become infected and about one in five of these patients will undergo a lower extremity amputation (LEA). In 2016 130,000 Americans were hospitalized for a LEA.
In Israel, around 75% of LEA’s are among diabetic patients and every year there are at least 1,500 LEA’s. The related economic burden is heavy. With effective treatment, many amputations can be prevented.
K-Sept 1000 provides powerful debridement. The patented K-Sept blue solution acts by softening of necrotic tissue, prevention of microbial growth, debris removal and exudate absorption.
K-Sept 1000 is supported by vast clinical experience. It comes in a box of 25 effervescent tablets and registered for “debridement, irrigation, hygiene and cleaning for wounds & skin”.
K-Sept 1000, with its powerful debridement capability, facilitates the critical shift from Inflammation to Granulation, thus paving the way to wound healing.
By Scope and Severity, by Economic Burden, by Psychosocial Impact
Effective – Safe – Proven – Easy to Use
Continuous renewal of solution on the wound (via frequent dressing wetting) is essential for facilitating wound healing.